Novo Nordisk's Experimental Diabetes Treatment Achieves Better Blood Sugar Targets Than Insulin Degludec

• Novo Nordisk A/S (NYSE: NVO) presented new data from the phase 3a ONWARDS 2 trial of insulin icodec in type 2 diabetes at the European Association for the Study of Diabetes Annual Meeting 2022.

• The data demonstrated that 37% of patients treated with once-weekly insulin icodec achieved an HbA1c <7.0% without experiencing severe or clinically significant hypoglycemia, compared with 27% of those treated with insulin deglude.

• Related: Novo Nordisk's Subcutaneous Semaglutide Shows Positive Action In Type 2 Diabetes.

• From a mean baseline of 8.17% (icodec) and 8.10% (degludec), once-weekly insulin icodec achieved a superior reduction in estimated HbA1c of 0.93% compared with 0.71% for insulin degludec.

• People with diabetes in ONWARDS 2 reported significantly greater satisfaction in favor of once-weekly insulin icodec than insulin degludec at 26 weeks.

• The mean weekly insulin dose was 268 U/week for insulin icodec vs. 244 U/week for insulin degludec. The mean change in body weight from baseline to week 26 was 1.40 kg for insulin icodec compared with –0.30 kg for insulin degludec.

• In the trial, once-weekly insulin icodec appeared to have a safe and well-tolerated profile.

• Price Action: NVO shares are down 1.17% at $98.06 on the last check Thursday.

See more from Benzinga

• BARDA Exercises First Contract Option With Marinus Pharma For Its Epilepsy Candidate

• Pfizer To Supply 6M COVID-19 Therapy Courses To Low Income Countries

• President Putin Suffering From 'Rapidly Progressing Cancer,' On Verge Of Losing Sight: Report

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.